A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
NCT ID: NCT03083704
Last Updated: 2023-08-08
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
153 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-02-26
Study Completion Date
2017-09-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a randomized, double-blind, study in healthy volunteers dosed to steady state with fXa inhibitors, designed to (1) demonstrate PK/PD comparability between andexanet manufactured by the Generation 1 and Generation 2 processes, (2) evaluate the degree to which the Generation 2 andexanet reverses fXa-inhibitor-induced anticoagulation in comparison to placebo, and (3) evaluate safety of Generation 2 andexanet.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
NCT03310021
Bleeding
COMPLETED
PHASE2
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing
NCT03330457
Bleeding
TERMINATED
PHASE2
A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
NCT02329327
Bleeding
COMPLETED
PHASE3
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)
NCT03551730
Healthy Volunteers
COMPLETED
PHASE2
A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
NCT02220725
Bleeding
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Bleeding
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Group Type
EXPERIMENTAL
Apixaban 5 MG
Intervention Type
DRUG
factor Xa inhibitor
Andexanet alfa (Gen 1 Process 3)
Intervention Type
BIOLOGICAL
factor Xa inhibitor antidote
Cohort 2
Group Type
EXPERIMENTAL
Rivaroxaban 20 MG
Intervention Type
DRUG
factor Xa inhibitor
Andexanet alfa (Gen 1 Process 3)
Intervention Type
BIOLOGICAL
factor Xa inhibitor antidote
Cohort 3
Group Type
EXPERIMENTAL
Andexanet alfa (Gen 1 Process 2)
Intervention Type
BIOLOGICAL
factor Xa inhibitor antidote
Apixaban 5 MG
Intervention Type
DRUG
factor Xa inhibitor
Cohort 4
Group Type
EXPERIMENTAL
Apixaban 5 MG
Intervention Type
DRUG
factor Xa inhibitor
Andexanet alfa (Gen 2)
Intervention Type
BIOLOGICAL
factor Xa inhibitor antidote
Cohort 5
Group Type
EXPERIMENTAL
Rivaroxaban 20 MG
Intervention Type
DRUG
factor Xa inhibitor
Andexanet alfa (Gen 2)
Intervention Type
BIOLOGICAL
factor Xa inhibitor antidote
Cohort 6
Group Type
EXPERIMENTAL
Enoxaparin sodium
Intervention Type
DRUG
low molecular weight heparin
Andexanet alfa (Gen 2)
Intervention Type
BIOLOGICAL
factor Xa inhibitor antidote
Cohort 7
Group Type
EXPERIMENTAL
Edoxaban 60 MG
Intervention Type
DRUG
factor Xa inhibitor
Andexanet alfa (Gen 2)
Intervention Type
BIOLOGICAL
factor Xa inhibitor antidote
Cohort 8
Group Type
EXPERIMENTAL
Andexanet alfa (Gen 2)
Intervention Type
BIOLOGICAL
factor Xa inhibitor antidote
Apixaban 10 MG
Intervention Type
DRUG
factor Xa inhibitor
Cohort 9
Group Type
EXPERIMENTAL
Andexanet alfa (Gen 2)
Intervention Type
BIOLOGICAL
factor Xa inhibitor antidote
Rivaroxaban 10 MG
Intervention Type
DRUG
factor Xa inhibitor
Cohort 10
Group Type
EXPERIMENTAL
Enoxaparin sodium
Intervention Type
DRUG
low molecular weight heparin
Andexanet alfa (Gen 2)
Intervention Type
BIOLOGICAL
factor Xa inhibitor antidote
Cohort 11
Group Type
EXPERIMENTAL
Edoxaban 60 MG
Intervention Type
DRUG
factor Xa inhibitor
Andexanet alfa (Gen 2)
Intervention Type
BIOLOGICAL
factor Xa inhibitor antidote
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Andexanet alfa (Gen 1 Process 2)
factor Xa inhibitor antidote
Intervention Type
BIOLOGICAL
Apixaban 5 MG
factor Xa inhibitor
Intervention Type
DRUG
Rivaroxaban 20 MG
factor Xa inhibitor
Intervention Type
DRUG
Enoxaparin sodium
low molecular weight heparin
Intervention Type
DRUG
Edoxaban 60 MG
factor Xa inhibitor
Intervention Type
DRUG
Andexanet alfa (Gen 2)
factor Xa inhibitor antidote
Intervention Type
BIOLOGICAL
Andexanet alfa (Gen 1 Process 3)
factor Xa inhibitor antidote
Intervention Type
BIOLOGICAL
Apixaban 10 MG
factor Xa inhibitor
Intervention Type
DRUG
Rivaroxaban 10 MG
factor Xa inhibitor
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Must be in reasonably good health as determined by the Investigator based on medical history, full physical examination (including blood pressure and pulse rate measurement), 12-lead ECG, and clinical laboratory tests. Subjects with well-controlled, chronic, stable conditions (e.g., controlled hypertension, non-insulin dependent diabetes, osteoarthritis, hypothyroidism) may be enrolled based on the clinical judgment of the Investigator and if approved by the Medical Monitor.
2. Must be between the ages of 18 and 75 years, inclusive, at the time of signing of the informed consent form (ICF).
3. Agrees to have any dietary or nutritional supplements reviewed by the Investigator and potentially be withheld during the study if advised by the Investigator. Standard multivitamin and mineral supplementation will be permitted.
4. Agrees to comply with the contraception and reproduction restrictions of the study:
* Men whose sexual partner is of childbearing potential and/or who are not monogamous must be using two acceptable methods of contraception, at least one of which must be a barrier method (e.g., spermicidal gel plus condom), for the entire duration of the study and for at least 1 month following study-drug administration; and men must refrain from attempting to father a child or donating sperm in the 1 month following the study-drug administration. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception;
* Men who report surgical sterilization (e.g., bilateral vasectomy) must have had the procedure at least 6 months before study drug administration.
* Surgical sterilization procedures should be supported with clinical documentation and noted in the Relevant Medical History/Current Medical Conditions section of the case report forms (CRFs).
* Women of childbearing potential must be using two medically acceptable methods of contraception, at least one of which must be a barrier method (e.g., non-hormone containing intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom), from the time of Screening and for the duration of the study, through at least 1 month following study drug administration. NOTE: Oral and topical hormonal contraceptive use, as well as the use of hormone-containing intra-uterine devices, is not permitted due to their increased risk of thromboembolism. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception; OR
* Postmenopausal women must have had no regular menstrual bleeding for at least 1 year before initial dosing and either be over the age of 60 years or have an elevated plasma follicle-stimulating hormone (FSH) level (i.e., \> 40 mIU/mL) at Screening; OR
* Women who report surgical sterilization (i.e., hysterectomy, tubal ligation, and/or bilateral oophorectomy) must have had the procedure at least 6 months before study drug administration. Surgical sterilization procedures should be supported with clinical documentation and noted in the Relevant Medical History/Current Medical Conditions section of the CRF; AND
* All female subjects must have a documented negative pregnancy test result at Screening and on Study Day 1.
5. Systolic blood pressure \< 160 mmHg and diastolic blood pressure \< 90 mmHg at Screening and Day 1.
6. The following laboratory values must be within the normal laboratory reference range within 28 days of Day 1: prothrombin time (PT), activated partial thromboplastin time (aPTT), and activated clotting time (ACT); hemoglobin, hematocrit, and platelet count.
7. The following laboratory values must be equal to or below 2 times the upper limit of normal (ULN) range within 28 days of Day 1: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) and total bilirubin.
8. The Screening serum creatinine must be below 1.5 mg/dL within 28 days of Day 1.
9. Body mass index between 19-30 kg/m2, inclusive, and body weight at least 50 kg.
10. Agrees to abstain from alcohol consumption for the duration of the domicile period, and from the use of drugs of abuse for the duration of the study.
11. Able to read and give written informed consent and has signed a consent form approved by the Investigator's Institutional Review Board (IRB) or Independent Ethics Committee (IEC).
2. Must be between the ages of 18 and 75 years, inclusive, at the time of signing of the informed consent form (ICF).
3. Agrees to have any dietary or nutritional supplements reviewed by the Investigator and potentially be withheld during the study if advised by the Investigator. Standard multivitamin and mineral supplementation will be permitted.
4. Agrees to comply with the contraception and reproduction restrictions of the study:
* Men whose sexual partner is of childbearing potential and/or who are not monogamous must be using two acceptable methods of contraception, at least one of which must be a barrier method (e.g., spermicidal gel plus condom), for the entire duration of the study and for at least 1 month following study-drug administration; and men must refrain from attempting to father a child or donating sperm in the 1 month following the study-drug administration. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception;
* Men who report surgical sterilization (e.g., bilateral vasectomy) must have had the procedure at least 6 months before study drug administration.
* Surgical sterilization procedures should be supported with clinical documentation and noted in the Relevant Medical History/Current Medical Conditions section of the case report forms (CRFs).
* Women of childbearing potential must be using two medically acceptable methods of contraception, at least one of which must be a barrier method (e.g., non-hormone containing intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom), from the time of Screening and for the duration of the study, through at least 1 month following study drug administration. NOTE: Oral and topical hormonal contraceptive use, as well as the use of hormone-containing intra-uterine devices, is not permitted due to their increased risk of thromboembolism. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception; OR
* Postmenopausal women must have had no regular menstrual bleeding for at least 1 year before initial dosing and either be over the age of 60 years or have an elevated plasma follicle-stimulating hormone (FSH) level (i.e., \> 40 mIU/mL) at Screening; OR
* Women who report surgical sterilization (i.e., hysterectomy, tubal ligation, and/or bilateral oophorectomy) must have had the procedure at least 6 months before study drug administration. Surgical sterilization procedures should be supported with clinical documentation and noted in the Relevant Medical History/Current Medical Conditions section of the CRF; AND
* All female subjects must have a documented negative pregnancy test result at Screening and on Study Day 1.
5. Systolic blood pressure \< 160 mmHg and diastolic blood pressure \< 90 mmHg at Screening and Day 1.
6. The following laboratory values must be within the normal laboratory reference range within 28 days of Day 1: prothrombin time (PT), activated partial thromboplastin time (aPTT), and activated clotting time (ACT); hemoglobin, hematocrit, and platelet count.
7. The following laboratory values must be equal to or below 2 times the upper limit of normal (ULN) range within 28 days of Day 1: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) and total bilirubin.
8. The Screening serum creatinine must be below 1.5 mg/dL within 28 days of Day 1.
9. Body mass index between 19-30 kg/m2, inclusive, and body weight at least 50 kg.
10. Agrees to abstain from alcohol consumption for the duration of the domicile period, and from the use of drugs of abuse for the duration of the study.
11. Able to read and give written informed consent and has signed a consent form approved by the Investigator's Institutional Review Board (IRB) or Independent Ethics Committee (IEC).
Exclusion Criteria
1. Previous use of andexanet or previous participation in the current study.
2. History of abnormal bleeding, signs or symptoms of active bleeding, or risk factors for bleeding.
3. Has a stool specimen that was positive for occult blood within 6 months of study Screening or during the Screening Period.
4. Past or current medical history of thrombosis, any sign or symptom that suggests an increased risk of a systemic thrombotic condition or thrombotic event, or recent events that may increase risk of thrombosis.
a. For example, subjects with a known or suspected hypercoagulable state, history of VTE, DVT, stroke, myocardial infarction \[MI\], cancer \[other than non-melanoma skin cancer\], atrial fibrillation, heart failure, cardiomyopathy, phlebitis, lower extremity edema, major surgery or trauma within 2 months of Study Day 1, airplane travel ≥ 2 hours during the 4 weeks prior to Study Day 1, or general immobility are excluded.
5. Absolute or relative contraindication to anticoagulation or treatment with apixaban, rivaroxaban, enoxaparin, or edoxaban.
6. Prior consumption of (by any route) one or more doses of aspirin (including baby aspirin), salicylate or subsalicylate, other antiplatelet drugs (e.g., ticlopidine, clopidogrel), non-steroidal anti-inflammatory drugs, fibrinolytic, or any anticoagulant within 7 days prior to Day 1 or is anticipated to require such drugs during the study.
7. Receipt of (by any route) hormonal contraception, post-menopausal hormone replacement therapy (HRT) (including over-the-counter products), or testosterone during the 4 weeks prior to Study Day 1 or is anticipated to require such drugs during the study.
8. Family history of or risk factors for a hypercoagulable or thrombotic condition, including one of the following:
1. Factor V Leiden carrier or homozygote.
2. Protein C, S, or ATIII activity below the normal range.
9. History of adult asthma or chronic obstructive pulmonary disease or current regular or as-needed use of inhaled medications.
10. Active HBV, HCV, or HIV-1/2 infection
11. Use of any drugs that are strong dual inhibitors or inducers of CYP3A4 and P-gp within 7 days prior to Study Day 1 or anticipated need for such drugs during the study.
12. Participation in an investigational drug study within 28 days of Day 1 or Day 1 is within 5 half-lives of the investigational compound.
13. Positive screen for drugs of abuse at Day 1 that is not explained by a prescription medication that the subject is known to be taking.
14. A medical or surgical condition that may impair drug (fXa inhibitor or andexanet) metabolism.
15. Allergy to any of the vehicle ingredients: tris, arginine, sucrose, hydrochloric acid, mannitol, and polysorbate 80.
16. Current breastfeeding or a positive pregnancy test at Screening or Day 1.
17. Any condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or interpretation of the study results, or that would in the opinion of the Investigator increase the risk of the subject's participation in the study. This would include but is not limited to alcoholism, drug dependency or abuse, psychiatric disease, epilepsy, or any unexplained blackouts.
18. The subject is not judged by the study staff to have adequate bilateral venous access.
19. Unwillingness to adhere to the activity requirements of the study.
2. History of abnormal bleeding, signs or symptoms of active bleeding, or risk factors for bleeding.
3. Has a stool specimen that was positive for occult blood within 6 months of study Screening or during the Screening Period.
4. Past or current medical history of thrombosis, any sign or symptom that suggests an increased risk of a systemic thrombotic condition or thrombotic event, or recent events that may increase risk of thrombosis.
a. For example, subjects with a known or suspected hypercoagulable state, history of VTE, DVT, stroke, myocardial infarction \[MI\], cancer \[other than non-melanoma skin cancer\], atrial fibrillation, heart failure, cardiomyopathy, phlebitis, lower extremity edema, major surgery or trauma within 2 months of Study Day 1, airplane travel ≥ 2 hours during the 4 weeks prior to Study Day 1, or general immobility are excluded.
5. Absolute or relative contraindication to anticoagulation or treatment with apixaban, rivaroxaban, enoxaparin, or edoxaban.
6. Prior consumption of (by any route) one or more doses of aspirin (including baby aspirin), salicylate or subsalicylate, other antiplatelet drugs (e.g., ticlopidine, clopidogrel), non-steroidal anti-inflammatory drugs, fibrinolytic, or any anticoagulant within 7 days prior to Day 1 or is anticipated to require such drugs during the study.
7. Receipt of (by any route) hormonal contraception, post-menopausal hormone replacement therapy (HRT) (including over-the-counter products), or testosterone during the 4 weeks prior to Study Day 1 or is anticipated to require such drugs during the study.
8. Family history of or risk factors for a hypercoagulable or thrombotic condition, including one of the following:
1. Factor V Leiden carrier or homozygote.
2. Protein C, S, or ATIII activity below the normal range.
9. History of adult asthma or chronic obstructive pulmonary disease or current regular or as-needed use of inhaled medications.
10. Active HBV, HCV, or HIV-1/2 infection
11. Use of any drugs that are strong dual inhibitors or inducers of CYP3A4 and P-gp within 7 days prior to Study Day 1 or anticipated need for such drugs during the study.
12. Participation in an investigational drug study within 28 days of Day 1 or Day 1 is within 5 half-lives of the investigational compound.
13. Positive screen for drugs of abuse at Day 1 that is not explained by a prescription medication that the subject is known to be taking.
14. A medical or surgical condition that may impair drug (fXa inhibitor or andexanet) metabolism.
15. Allergy to any of the vehicle ingredients: tris, arginine, sucrose, hydrochloric acid, mannitol, and polysorbate 80.
16. Current breastfeeding or a positive pregnancy test at Screening or Day 1.
17. Any condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or interpretation of the study results, or that would in the opinion of the Investigator increase the risk of the subject's participation in the study. This would include but is not limited to alcoholism, drug dependency or abuse, psychiatric disease, epilepsy, or any unexplained blackouts.
18. The subject is not judged by the study staff to have adequate bilateral venous access.
19. Unwillingness to adhere to the activity requirements of the study.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Portola Pharmaceuticals
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West Coast Clinical Trials
Cypress, California, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-512
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
NCT02207725
COMPLETED
PHASE3
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)
NCT01758432
COMPLETED
PHASE2
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)
NCT03551743
COMPLETED
PHASE2
A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
NCT03891524
COMPLETED
PHASE2
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
NCT07312851
NOT_YET_RECRUITING
PHASE1
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)
NCT03578146
COMPLETED
PHASE2
Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
NCT00375609
COMPLETED
PHASE2
Prevention of Thromboembolic Events in Total Knee Replacement Patients
NCT03393481
WITHDRAWN
PHASE2
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
NCT01662908
COMPLETED
PHASE2
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
NCT00452530
COMPLETED
PHASE3
Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin
NCT00742859
COMPLETED
PHASE2
Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
NCT00371683
COMPLETED
PHASE3
Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects
NCT05491460
UNKNOWN
PHASE1
Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote
NCT03218241
COMPLETED
PHASE1
A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery
NCT03251482
COMPLETED
PHASE2
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
NCT00402467
COMPLETED
PHASE2
Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban
NCT04169269
UNKNOWN
PHASE4
Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism
NCT02977013
COMPLETED
The Effect of Prophylactic Anticoagulation on Major Bleeding Events in Hospitalized Chronic Kidney Disease and Lower Limb Fracture Patients.
NCT06795698
COMPLETED
PHASE2
Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
NCT02933697
COMPLETED
PHASE3
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
NCT00457002
COMPLETED
PHASE3
Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
NCT02270918
COMPLETED
PHASE1
Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers
NCT03363477
COMPLETED
PHASE1
Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
NCT00398905
COMPLETED
PHASE2
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
NCT02064439
COMPLETED
PHASE3